ACA
IBRX icon

American Capital Advisory’s ImmunityBio IBRX Stock Holding History

American Capital Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Buy
1,227
+60
+5% +$454 ﹤0.01% 354
2026
Q1 		$8.95K Buy
+1,167
New +$7.99K ﹤0.01% 346

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

American Capital Advisory's IBRX Position: Q2 2026 in Review

American Capital Advisory increased its ImmunityBio (IBRX) stake by 5.1% in Q2 2026, buying an estimated $454 and bringing the position to 1,227 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #354.

American Capital Advisory first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • American Capital Advisory held 1,227 shares of ImmunityBio worth $10.7K as of Q2 2026.
  • American Capital Advisory bought 60 ImmunityBio shares in Q2 2026, an estimated $454.
  • ImmunityBio made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #354 holding.
  • American Capital Advisory first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.